Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Conclusion: This indirect treatment comparison suggests, relative to cabozantinib, regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and disc ontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue.
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research